•
Dec 31, 2024

Akero Q4 2024 Earnings Report

Expected Revenue:$0
Expected EPS:-$0.98
19.5% YoY

Key Takeaways

Akero Therapeutics announced its financial results for the quarter and full year ended December 31, 2024.

Akero Therapeutics announced Q4 and full year 2024 financial results.

Press release with financial results was furnished as an exhibit.

The information is not deemed filed for liability purposes.

Andrew Cheng, M.D., Ph.D., President and CEO, signed the report.

Akero

Akero